Literature DB >> 33409801

Perception of Illness and Its Association with Treatment Willingness in Patients with Newly Diagnosed Nonalcoholic Fatty Liver Disease.

Harpal S Dhaliwal1, Ripudaman Singh2, Abin M Abraham3, Rajan Sharma4, N K Goyal5, Rajat Soloman6, Pankaj Bansal7, Amandeep Goyal8.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease of immense public health relevance. Understanding illness perceptions in the NAFLD population will provide sound scientific evidence for planning high-quality patient-centered care and implementing effective interventions. The Brief Illness Perception Questionnaire (BIPQ) is a robust psychometric tool to systematically assess the dimensions of illness perceptions in various chronic ailments.
METHODS: In a cross-sectional study enrolling patients with newly diagnosed NAFLD, the sociodemographic, anthropometric, biochemical, and radiological determinants of enhanced illness perceptions (measured by the BIPQ score) were investigated using univariate and multivariable binary logistic regression analyses. Finally, the association between individual domains of the BIPQ and willingness to participate in comprehensive medical management was explored.
RESULTS: In total, 264 patients (mean age 53 ± 11.9 years, 59.8% males) were enrolled in the final analysis. The mean and median BIPQ scores in the study population were 30.3 ± 12.8 and 31.0 (IQR, 22.0-40.0), respectively. The variables having a significant independent association with heightened perceptions (BIPQ > 31) were family history of liver disease (aOR, 5.93; 95% CI, 1.42-24.74), obesity (aOR, 3.33; 95% CI, 1.57-7.05), diabetes mellitus (aOR, 2.35; 95% CI, 1.01-5.49), and transaminitis (aOR, 2.85; 95% CI, 1.42-5.69). Patients with a higher level of illness perceptions (31.6 ± 12.9 vs 27.8 ± 12.3, p = 0.022) were more likely to express a willingness to participate in the comprehensive management plan, with 3 of the 8 domains (consequence, identity, and treatment control) mainly affecting willingness.
CONCLUSION: A family history of liver disease, obesity, diabetes, and transaminitis were independently associated with increased illness perceptions. A belief in serious consequences, a strong illness identity, and higher perceived treatment control were significantly associated with the willingness to undergo comprehensive care for NAFLD.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  BIPQ; Brief Illness Perception Questionnaire; Illness perceptions; NAFLD; Nonalcoholic fatty liver disease

Mesh:

Year:  2021        PMID: 33409801     DOI: 10.1007/s10620-020-06794-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  48 in total

1.  The brief illness perception questionnaire.

Authors:  Elizabeth Broadbent; Keith J Petrie; Jodie Main; John Weinman
Journal:  J Psychosom Res       Date:  2006-06       Impact factor: 3.006

Review 2.  Non-alcoholic fatty liver disease: The diagnosis and management.

Authors:  Shehab M Abd El-Kader; Eman M Salah El-Den Ashmawy
Journal:  World J Hepatol       Date:  2015-04-28

Review 3.  A systematic review and meta-analysis of the Brief Illness Perception Questionnaire.

Authors:  Elizabeth Broadbent; Carissa Wilkes; Heidi Koschwanez; John Weinman; Sam Norton; Keith J Petrie
Journal:  Psychol Health       Date:  2015-08-26

4.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Authors:  Arun J Sanyal; Naga Chalasani; Kris V Kowdley; Arthur McCullough; Anna Mae Diehl; Nathan M Bass; Brent A Neuschwander-Tetri; Joel E Lavine; James Tonascia; Aynur Unalp; Mark Van Natta; Jeanne Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck
Journal:  N Engl J Med       Date:  2010-04-28       Impact factor: 91.245

5.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

Authors:  C A Matteoni; Z M Younossi; T Gramlich; N Boparai; Y C Liu; A J McCullough
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

Review 6.  Nonalcoholic fatty liver disease: from steatosis to cirrhosis.

Authors:  Geoffrey C Farrell; Claire Z Larter
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

Review 7.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

8.  Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease.

Authors:  Lisa B VanWagner; Mary E Rinella
Journal:  Curr Hepatol Rep       Date:  2016-03-28

9.  Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.

Authors:  Giovanni Targher; Christopher D Byrne; Amedeo Lonardo; Giacomo Zoppini; Corrado Barbui
Journal:  J Hepatol       Date:  2016-05-17       Impact factor: 25.083

10.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

Authors:  Matthew James Armstrong; Piers Gaunt; Guruprasad P Aithal; Darren Barton; Diana Hull; Richard Parker; Jonathan M Hazlehurst; Kathy Guo; George Abouda; Mark A Aldersley; Deborah Stocken; Stephen C Gough; Jeremy W Tomlinson; Rachel M Brown; Stefan G Hübscher; Philip N Newsome
Journal:  Lancet       Date:  2015-11-20       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.